Supplemental Table 1. Reagents used in the B cell staining panel.

|  |  |  |
| --- | --- | --- |
| **Antibody** | **Manufacturer** | **Clone** |
| CD3 BV510 | BD Biosciences | HIT3a |
| CD14 BV510 | BD Biosciences | MφP9 |
| CD56 BV510 | BD Biosciences | NCAM16.2 |
| CD19 BUV395 | BD Biosciences | SJ25-C1 |
| CD20 BUV737 | BD Biosciences | 2H7 |
| CD21 PE-Cy7 | BD Biosciences | B-ly4 |
| CD27 BV605 | BioLegend | O323 |
| CD38 BB700 | BD Biosciences | HIT2 |
| IgA VioBlue | Miltenyi Biotec | IS11-8E10 |
| IgD BV650 | BD Biosciences | IA6-2 |
| IgG BV786 | BD Biosciences | G18-145 |
| IgM PE/Dazzle 594 | BioLegend | MHM-88 |
| R-Phycoerythrin Streptavidin | Invitrogen | N/A |
| AlexaFluor 488 Streptavidin | Invitrogen | N/A |
| AlexaFluor 647 Streptavidin | Invitrogen | N/A |
| LIVE/DEAD Fixable Aqua Stain | Invitrogen | N/A |


APC, allophycocyanin; BB, brilliant blue; BUV, brilliant ultraviolet; BV, brilliant violet; Cy, cyanine; FITC, fluorescein isothiocyanate; PE R-phycoerythrin; UViD, Live/Dead fiaxable ultraviolet dead cell stain

# Supplemental Table 2. T cell intracellular cytokine staining flow cytometry panel.


|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Specificity** | **Fluorochrome** | **Clone** | **Vendor** | **Catalogue** |
|
| Perforin | FITC | B-D48 | BioLegend | 353310 |
| IL-5 | BB630 | TRFK5 | BD | Custom |
| IL-13 | BB630 | JES10-5A2 | BD | Custom |
| Ki67 | BB660 | B56 | BD | Custom |
| IL-4 | BB700 | MP4-25D2 | BD | Custom |
| CRTh2 | PE | BM16 | BioLegend | 350106 |
| CD32 | PE-Dazzle594 | FUN-2 | BioLegend | 303218 |
| CXCR3 (CD183) | PE-Cy5 | 1C6/CXCR3 | BD | 551128 |
| FOXP3 | PE-Cy5.5 | PCH101 | Invitrogen | 35-4776-42 |
| IL-17a | PE-Cy7 | BL168 | BioLegend | 512315 |
| IL-2 | APC | MQ1-17H12 | BioLegend | 500310 |
| Granzyme B | Alexa 700 | GB11 | BD | 560213 |
| CD3 | APC-Fire750 | UCHT1 | BioLegend | 300470 |
| TNF | BUV395 | MAb11 | BD | 563996 |
| Viability | UViD | N/A | Invitrogen | 65-0863 |
| CD45RA | BUV496 | HI100 | BD | 750258 |
| CD19 | BUV563 | SJ25C1 | BD | 612916 |
| CD14 | BUV661 | MΦP9 | BD | 741684 |
| CD154 | BUV737 | TRAP1 | BD | 748983 |
| CD8 | BUV805 | SK1 | BD | 612889 |
| IFNγ | V450 | B27 | BD | 560371 |
| CD4 | BV480 | SK3 | BD | 566104 |
| CD16 | BV570 | 3G8 | BioLegend | 302036 |
| CCR7 | BV605 | G034H7 | BioLegend | 353224 |
| CD25 | BV650 | M-A251 | BD | 563719 |
| CD64 | BV711 | 10.1 | BioLegend | 305042 |
| CD56 | BV750 | 5.1H11 | BioLegend | 362556 |
| CCR6 (CD196) | BV786 | 11A9 | BD | 563704 |



**Figure S1.** Viral dilutions yielding similar relative infectivity of Wuhan-Hu-1 and B.1.351 pseudoviruses in 293-ACE2 cells in the absence of antibody or sera were employed during neutralization experiments. Each dot represents the average entry of meausred n=8 replicate wells from an individual assay plate corresponding to the data shown in Figure Figure 3. The entry of pseudoviral particles produced without transfection with a spike-encoding plasmid are shown for comparison. (Δspike) The background is the luciferase signal obtained from n=8 replicate wells to which neither virus was added. The bars represent the mean and the error bars represent the SD.

****

**Figure S2.** Binding of the indicated mAbs was measured to (**A**) SARS-CoV-2 S2P, (**B**) SARS-CoV-2 RBD, (**C**) SARS-CoV-2 S1 NTD, and (**D**) SARS CoV-2 S2 by BLI.



**Figure S3.** Frequency of S-specific IgM memory B cells (live, IgD-, CD19+, CD20+, CD3-, CD14-, CD56-, singlet, lymphocytes) before and after immunization.

A picture containing purple, dark, outdoor object

Description automatically generated

**Figure S4**. The ability of sera from donors who recovered from SARS-CoV-2 were evaluated for their ability to neutralize the Wuhan Hu1 and B.1.351 pseudovirus infectivity before and after immunization as indicated. Serum collected from two donors prior to the pandemic were included as controls. Data is represenative of two independent experiments.

**Figure S5:** No significant correlation between pre-vaccination neutralization responses to Wuhan Hu1 or B.1.351 variant (mutant) spike. r, Spearman rank correlation.

A picture containing text, receipt

Description automatically generated

**Figure S6**. No significant correlation between post-vaccination neutralization responses to Wuhan Hu1 or B.1.351 variant (mutant) spike. r, Spearman rank correlation.

Chart, diagram

Description automatically generated

**Figure S7**. No significant differences in pre-vaccination neutralization responses to Wuhan Hu1 or B.1.351 variant (mutant) spike seen by WHO scale (2 vs. 3). p, Wilcoxon rank sum p-values.

Diagram

Description automatically generated

**Figure S8.** No significant differences in post-vaccination neutralization responses to Wuhan Hu1 or B.1.351 variant (mutant) spike seen by WHO scale (2 vs. 3). p, Wilcoxon rank sum p-values.

A picture containing outdoor object, purple

Description automatically generated

**Figure S9.** The ability of serum from donors who recovered from SARS-CoV-2 were evaluated for their ability to neutralize SARS-CoV-1 infectivity before and after immunization as indicated. Serum collected from two donors prior to the pandemic were included as controls.